These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8211308)

  • 21. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
    Hale VG; Woo K; Lipton HL
    Health Aff (Millwood); 2005; 24(4):1057-63. PubMed ID: 16012146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [On misery coast. Episode 1: the market of vital drugs].
    Chneiweiss H
    Med Sci (Paris); 2003; 19(8-9):892-4. PubMed ID: 14593623
    [No Abstract]   [Full Text] [Related]  

  • 23. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China.
    Lee VC; Yao J; Zhang W
    Global Health; 2021 Sep; 17(1):101. PubMed ID: 34488801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The economics of essential drug programmes.
    Smith GT
    Soc Sci Med; 1987; 25(6):621-4. PubMed ID: 3686096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Availability of medicines in the European Union: results from the EURO-Medicines project.
    Folino-Gallo P; Walley T; Frolich JC; Carvajal A; Edwards IR
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):441-6. PubMed ID: 11699607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The drug trade between European countries and developing countries].
    Bruneton C; Naboulet P; van der Heide B; Rey JL
    Med Trop (Mars); 1997; 57(4):375-9. PubMed ID: 9612781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study.
    Meyers DE; Meyers BS; Chisamore TM; Wright K; Gyawali B; Prasad V; Sullivan R; Booth CM
    Cancer; 2022 Jan; 128(2):311-316. PubMed ID: 34614198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Europe's drug companies are better than those in US in making drugs accessible to poor countries.
    Jack A
    BMJ; 2008 Jun; 336(7658):1396. PubMed ID: 18566062
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceutical policies for the Third World--whose responsibility?
    Lancet; 1983 Jul; 2(8342):144. PubMed ID: 6134987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Health Assembly:
    Turner J
    Lancet; 1984 May; 1(8387):1172-3. PubMed ID: 11644284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The economics of pharmaceutical supply in Tanzania.
    Yudkin JS
    Int J Health Serv; 1980; 10(3):455-77. PubMed ID: 7419314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access to essential drugs.
    Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany.
    Shibata S; Uemura R; Suzuki T
    Ther Innov Regul Sci; 2016 Mar; 50(2):221-227. PubMed ID: 30227003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Breaking the bureaucracy": drug registration and neocolonial relations in Egypt.
    Rubinstein RA
    Soc Sci Med; 1998 Jun; 46(11):1487-94. PubMed ID: 9665578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.